Names Under Consideration
USAN Council's statement on the use of USAN as domain names:
A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.
Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.
In order to ensure your "Under Consideration" USAN domain name is available, USAN applicants should consider purchasing the .com, .net, and .org domain names of your USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following list of names for the drugs described are "under consideration" by the USAN Council:
|inotersen||treatment of transthyretin-mediated amyloidosis|
|itacitinib||treatment of psoriasis, arthritis, solid tumors|
|onvelcitinib||treatment of psoriasis, arthritis, solid tumors|
|myoinositol||treatment of Retinopathy of Prematurity (ROP)|
|parmetinostat||treatment of early stage cutaneous T-cell lymphoma|
There are no applicable "names under consideration"
|alcanezumab||treatment of migraine|
|andepatuzumab mafodotin||treatment of cancer|
|cibinetide||reduction in neuropathic pain|
|clecinimod||treatment of chronic inflammatory disorders|
|domagrozumab||treatment of Duchenne muscular dystrophy|
|dulosurad||chronic management of hyperuricemia in patients with gout|
|ermenkumab||cachexia, oncology, vascular disease, type 2 diabetes|
|ferric pyrophosphate citrate||prevention and treatment of iron deficiency|
|lanadelumab||prevention of angioedemia in patients with hereditary angioedema|
|mozanatinib||treatment of cancer|
|pegapamodutide||treatment of diabetes/obesity|
|prexasertib||treatment of advance cancer|
|rarenlizumab||treatment of cancer|
|raxatrigine||treatment of neuropathic pain|
|sespribuvir||treatment of hepatitis C|
|tagutuzumab||treatment of CD19 positive hematologic malignancies|
|vadadustat||treatment of anemia associated with kidney disease|